James E Crowe, Jr

This inventor holds 45 USPTO granted patents and 18 published patent applications and 2 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Vanderbilt University, The University of Texas System, Johns Hopkins University. Active years: 1998-2026.

USPTO Granted Patents = 45 (Patent Applications = 18)

% Patents Active = 82.2

EPO Patents = 2 (Patent Applications = 16)

Average Co-Inventor Count = 2.1

ph-index = 7

Forward Citations = 240(Granted Patents)

Location History:

Chevy Chase, MD (US) (1998 - 2008)
Brentwood, TN (US) (2009 - 2012)
Nashville, TN (US) (2011 - 2024)

Company Filing History:

37 out of 1,218

Vanderbilt University

patents

5 out of 5,622

The University of Texas System

patents

3 out of 3,790

Johns Hopkins University

patents

4. 3 out of 1,203

Scripps Research Institute

patents

5. 3 out of 2,645

University of Pennsylvania

patents

6. 2 out of 3

Intracel Resources LLC

patents

7. 2 out of 1,322

The University of North Carolina at Chapel Hill

patents

8. 1 out of 1,567

American Home Products Corporation

patents

9. 1 out of 614

Baylor College of Medicine

patents

10. 1 out of 535

Icahn School of Medicine at Mount Sinai

The United States of America

patents

13. 1 out of 1,217

The United States of America as Represented by the Department of Health

patents

14. 1 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

SARS-CoV-2

Chikungunya Virus

Influenza A

Hepatitis C

Zika Virus

Ebola Virus

Hantavirus

Dengue Virus

Respiratory Syncytial Virus

Vaccine Development

Neutralizing Antibodies

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12703739 - HUMAN ANTIBODIES TO RIFT VALLEY FEVER VIRUS (2026-08-11),

2. 12699092 - HUMAN ANTIBODIES TO CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS (2026-08-04),

3. 12642847 - HUMAN MONOCLONAL ANTIBODIES TO VENEZUELAN EQUINE ENCEPHALITIS VIRUS AND USES THEREFOR (2026-06-02),

4. 12559545 - HUMAN HENDRA VIRUS AND NIPAH VIRUS ANTIBODIES AND METHODS OF USE THEREFOR (2026-02-24),

5. 12534512 - HUMAN MONOCLONAL ANTIBODIES TO HANTAVIRUS AND METHODS OF USE THEREFORE (2026-01-27),

6. 12496336 - PEPTIDE VACCINE BASED ON A NEW UNIVERSAL INFLUENZA A HEMAGGLUTININ HEAD DOMAIN EPITOPE AND HUMAN MONOCLONAL ANTIBODIES BINDING THERETO (2025-12-16),

7. 12410241 - Human monoclonal antibodies to enterovirus D68 (2025-09-09),

8. 12233127 - Human monoclonal antibodies to a new universal influenza A hemagglutinin head domain epitope (2025-02-25),

9. 12226471 - Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus (2025-02-18),

10. 12216120 - Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2025-02-04),

11. 12188053 - Human monoclonal antibodies that neutralize pandemic GII.4 noroviruses (2025-01-07),

12. 12037384 - Human monoclonal antibodies against yellow fever virus and uses therefor (2024-07-16),

13. 12024555 - Human West Nile virus antibodies and methods of use therefor (2024-07-02),

14. 11992520 - Human monoclonal antibodies toIsd proteins and uses thereof (2024-05-28),

15. 11957745 - Human Japanese Encephalitis Virus antibodies and methods of use therefor (2024-04-16),

Title: James E Crowe, Jr: A Pioneer in Biotechnology Innovation

Introduction:

James E Crowe, Jr, hailing from Nashville, TN, is a distinguished inventor known for his remarkable passion for innovation in the field of biotechnology. With a total of 24 patents to his name, he has displayed a deep commitment to improving global health through his revolutionary inventions.

Latest Patents:

Crowe's latest patents include "Human monoclonal antibodies to Isd proteins and uses thereof", which focuses on antibodies binding to and inhibiting certain proteins, and "Human Japanese Encephalitis Virus antibodies and methods of use therefor", highlighting antibodies that neutralize the Japanese Encephalitis virus.

Career Highlights:

Having worked at prestigious institutions like Vanderbilt University and the University of Texas System, Crowe has honed his expertise in biotechnology. His career is adorned with groundbreaking inventions that have the potential to shape the future of global health.

Collaborations:

Throughout his career, Crowe has collaborated with notable individuals in the field, including Andrew I Flyak and Alexander Bukreyev. These collaborations have led to the development of innovative solutions that have the capability to revolutionize the biotechnology sector.

Conclusion:

In conclusion, James E Crowe, Jr stands as a true pioneer in biotechnology, with his relentless pursuit of innovation and dedication to improving global health setting him apart in the industry. His inventive spirit continues to inspire future generations of inventors and researchers in the field.